Form D · Biotechnology
Kiyatec Inc.
Greenville, SC · CIK 0001547577
Offering snapshot reported Nov 6, 2024 · SEC filing
- Reported sold
- $250K Offering amount: $5.41M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Oct 22, 2024 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 6, 2024 | Amendment | $250,000 | $0vs Nov 6, 2024 | 1 | SEC filing |
| Nov 6, 2024 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Dec 9, 2022 | Initial | $18,057,766 | No comparison | 23 | SEC filing |
| Mar 11, 2019 | Initial | $5,330,777 | No comparison | 15 | SEC filing |
| Nov 27, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Oct 28, 2016 | Amendment | $3,148,408 | No comparison | 24 | SEC filing |
| Nov 6, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Dec 8, 2014 | Initial | $180,000 | No comparison | 3 | SEC filing |
| Apr 28, 2014 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Apr 17, 2012 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $207K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-528743
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Finalis Securities LLC | 305908 | Nicholas McFarland · CRD 7788555 |
Source: Form D, filed Nov 6, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Brotherton | Director |
| Christine Dixon Thiesing | Director |
| Martin Ettlemyer | Director |
| Matthew Gevaert | Director |
| H. Lee Higdon Iii | Director |
| Scott Isacksen | Executive |
| Bruce Nash | Director |
| David E Orr | Executive |
| Eric Perreault | Director, Executive |
| Melissa Rayner | Executive |
| Jason Robart | Director |
| Bob Silverman | Director |
| Robert Silverman | Director |
| Christine Dixon Thiesing | Director |
| Gregory Zaic | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:Greenville, SC, 29601